How Other Countries Treat Opioid Addiction: A Comparison

When Americans hear about medication-assisted treatment for opioid use disorder, the conversation often centers on what's allowed, what's stigmatized, and what's politically possible. But beyond our borders, other countries have tried dramatically different approaches — some with remarkable results. Understanding what works elsewhere doesn't mean copying policies wholesale, but it does offer valuable perspective on what's possible when evidence leads policy.

This isn't about declaring one country's approach "best" or advocating for wholesale adoption of foreign models. Cultural contexts differ, political realities vary, and healthcare systems operate under different constraints. Instead, this is an informational look at how five countries — Canada, Switzerland, Portugal, France, and Australia — structure their opioid treatment systems, what outcomes they've achieved, and what lessons might translate to the American context.

The goal isn't to say "why can't we be more like them?" It's to ask: what evidence-based elements could improve access and outcomes here?

Canada: Safe Supply and Harm Reduction Integration

Canada's approach to opioid addiction treatment has evolved significantly, particularly in response to the fentanyl crisis that has devastated communities across the country. Beyond expanding access to medications like buprenorphine (the active ingredient in Suboxone), some provinces have pioneered "safe supply" programs.

Safe supply means prescribing pharmaceutical-grade opioids to people at high risk of overdose from the contaminated street drug supply. The idea is simple: if someone is going to use opioids anyway, providing a predictable, measured dose eliminates the risk of fentanyl and other deadly adulterants.

What safe supply looks like in practice

British Columbia launched safe supply programs in several cities, allowing doctors to prescribe hydromorphone tablets as an alternative to street drugs. Patients receive daily or every-other-day supplies from pharmacies, similar to how methadone programs operate.

Early data suggests these programs reduce overdose deaths and keep people connected to healthcare. Critics worry about diversion (pills being sold rather than used), but proponents argue that saving lives takes priority, and diversion rates remain relatively low when programs include regular medical check-ins.

Lessons for the US

Safe supply remains politically controversial in the United States, where even evidence-based harm reduction approaches face significant resistance. However, Canada's model demonstrates that meeting people where they are — even if that means prescribing opioids to people actively using — can be a bridge to more comprehensive treatment.

The US already does something similar with medications like buprenorphine, which is itself an opioid. The difference is mostly philosophical: do we only prescribe opioids when someone is ready to stop other use, or do we prescribe them to prevent overdose deaths even during active use? Canada has leaned toward the latter, with measurable life-saving results.

Switzerland: Heroin-Assisted Treatment and Pragmatic Policy

Switzerland's approach to opioid addiction shocked the world in the 1990s, but the results speak for themselves. Faced with a public health crisis centered in Zurich's "Needle Park," the Swiss government launched heroin-assisted treatment (HAT) programs that prescribed pharmaceutical heroin to people for whom other treatments had failed.

How heroin-assisted treatment works

Patients come to clinics two or three times daily to use pharmaceutical-grade heroin under medical supervision. They're observed for safety, have access to nurses and counselors, and gradually stabilize their lives. Many eventually transition to buprenorphine or methadone, while others remain on heroin-assisted treatment long-term.

Studies of Swiss HAT programs show dramatic improvements: reduced criminal activity, better employment rates, improved physical health, and significantly lower mortality. Importantly, these programs didn't increase drug use in surrounding areas or attract new users. Instead, they reached people who had cycled through other treatments without success.

Why it works

HAT programs acknowledge a difficult reality: some people aren't ready to stop using opioids, but they still deserve healthcare and a path toward stability. By removing the need to acquire drugs illegally, these programs eliminate the chaos and danger that often accompanies untreated opioid use disorder.

The Swiss model is highly structured — this isn't a free-for-all. Eligibility requires documented treatment failures with other medications, and programs include comprehensive social services. The goal remains recovery, but it defines recovery as improved quality of life rather than complete abstinence as the only acceptable outcome.

US context and cultural barriers

Heroin-assisted treatment faces enormous political and cultural barriers in the United States. The very idea of prescribing heroin — the substance most Americans associate with addiction — seems counterintuitive. Yet Switzerland's three decades of evidence show that for a specific subset of patients, it saves lives and improves outcomes better than alternatives.

A few US cities have explored pilot programs, but none have launched at scale. The primary barriers are regulatory (heroin is Schedule I federally, unlike in Switzerland) and political. However, as evidence-based policy advocacy grows stronger, conversations about what's possible may shift.

Portugal: Decriminalization and Health-Centered Approach

Portugal's 2001 decriminalization of all drugs for personal use remains one of the most studied policy experiments in the world. It's often misunderstood — drugs aren't legal in Portugal, but possession of small amounts is treated as an administrative violation rather than a criminal offense.

What decriminalization changed

Before 2001, Portugal had Europe's highest rate of HIV among people who inject drugs and a growing overdose crisis. The government shifted from a criminal justice approach to a public health model. People caught with drugs face "dissuasion commissions" — panels of social workers, lawyers, and healthcare providers who assess needs and recommend treatment, not punishment.

Treatment is voluntary but encouraged, and Portugal invested heavily in expanding access to medication-assisted treatment, harm reduction services, and social support programs. Crucially, the policy change came with funding — decriminalization alone wouldn't have worked without robust treatment infrastructure.

Outcomes two decades later

Portugal's overdose death rate remains among the lowest in Europe. HIV infections among people who inject drugs dropped dramatically. Drug use rates stayed stable or declined slightly, debunking fears that decriminalization would lead to rampant addiction. Perhaps most importantly, thousands of people accessed treatment who would have hidden their drug use to avoid criminal consequences.

What this means for the US

Some US jurisdictions have implemented limited decriminalization (Oregon tried and recently reversed course), but the Portuguese model's success depended on the full package: decriminalization plus robust, accessible treatment. Simply removing criminal penalties without investing in care infrastructure misses the point.

The lesson isn't necessarily "decriminalize everything," but rather that removing criminal barriers to treatment while simultaneously expanding access works better than either approach alone. The US already struggles with treatment access in rural areas and insurance barriers — addressing those gaps matters more than decriminalization alone.

Telehealth treatment like Grata Health offers addresses some access barriers by eliminating geography as an obstacle, particularly in Virginia, Ohio, and Pennsylvania.

France: Pharmacy-Based Buprenorphine and Normalized Care

France took a radically different approach to expanding medication-assisted treatment: they made it ordinary. In the mid-1990s, French policymakers allowed general practitioners to prescribe buprenorphine without special training, and pharmacies to dispense it just like any other medication.

How France normalized buprenorphine

Unlike the US system (which until recently required special waivers for buprenorphine prescribing), French doctors treat opioid use disorder like any other chronic condition. There's no registry, no special DEA number, no stigma-laden bureaucracy. Patients fill prescriptions at regular pharmacies alongside people picking up blood pressure medication.

This normalization dramatically increased access. Within a few years, over 80,000 French patients were receiving buprenorphine treatment — far more than were enrolled in methadone programs. Overdose deaths dropped by 79% between 1995 and 1999.

The pharmacy model's advantages

Making treatment available through primary care and pharmacies removes multiple barriers: the need to travel to specialized clinics, the visibility of attending addiction-specific programs, and the sense that opioid use disorder requires exceptional intervention rather than standard medical care.

France's model isn't perfect — some critics point to diversion concerns and argue that some patients need more intensive support than primary care provides. But for many people, the low-barrier pharmacy model offers a crucial entry point into treatment that might otherwise feel unreachable.

US parallels and differences

The elimination of the X-waiver requirement in the US moved us closer to the French model, allowing any DEA-registered prescriber to offer buprenorphine. However, significant barriers remain: many providers still hesitate to prescribe due to stigma, prior authorization requirements create delays, and patient assistance often depends on counseling mandates that pharmacy-based models typically don't require.

The US could learn from France's emphasis on making treatment feel normal rather than exceptional. When telehealth providers like Grata Health offer video appointments that feel like any other doctor's visit, they're applying a similar principle: treatment works better when it doesn't feel like an ordeal.

Australia: Flexible Take-Home Dosing and Patient Autonomy

Australia's opioid treatment system emphasizes progression toward patient autonomy through flexible take-home dosing policies for both methadone and buprenorphine. While treatment typically starts with supervised daily dosing at pharmacies, patients can relatively quickly earn take-home doses based on stability rather than arbitrary timeframes.

How take-home dosing works down under

Australian patients work with their prescribers to establish stability — consistent attendance, negative drug screens, safe storage at home. Once stable, they can receive weekly or even monthly supplies to take home, eliminating daily pharmacy visits.

This model recognizes that daily clinic attendance can be a barrier to employment, education, and normal life. A person who has to be at a pharmacy every morning at 6 AM struggles to maintain a regular job. Take-home dosing removes that constraint while still providing medical oversight through regular check-ins.

Evidence for flexibility

Studies of Australian patients on take-home dosing show high retention rates and outcomes comparable to daily supervised dosing. The key is appropriate assessment — not everyone is suitable for take-homes immediately, but many patients who are denied them in other countries could safely manage them.

The US has traditionally been much more restrictive, particularly with methadone (which requires daily observed dosing for extended periods). Buprenorphine prescribing allows for more flexibility, and telehealth has enabled monthly prescriptions with regular video check-ins, but the US still lags behind Australian policies.

Patient-centered progression

Australia's model treats progression to take-home dosing as a clinical decision based on individual circumstances rather than a universal timeline. This respects patient autonomy and acknowledges that people in recovery benefit from the dignity of managing their own medication.

Some US jurisdictions loosened take-home policies during COVID-19 and saw positive results, suggesting that American patients could handle more flexibility than regulations traditionally allowed. The question is whether those temporary changes will become permanent improvements.

What the US Does Well (and Less Well)

It's important to note that the US isn't doing everything wrong. The country has made significant progress in recent years: elimination of the X-waiver requirement, expansion of telehealth prescribing, increased naloxone access, and growing recognition that medication-assisted treatment works.

The US also leads in certain areas of addiction research and has developed effective counseling models that complement medication. The integration of mental health care with addiction treatment is increasingly common, addressing the high rates of comorbidity between opioid use disorder and conditions like depression and anxiety.

Where the US struggles most is consistency and equity. Treatment availability varies wildly by geography, insurance status, and state policy. Someone in Virginia may have excellent Medicaid coverage for buprenorphine, while someone in a non-expansion state faces impossible barriers. Rural patients often have no local providers, and insurance authorization requirements create delays even when coverage exists.

The countries discussed above generally offer more universal access, though each has its own gaps and challenges. The lesson isn't that they've perfected treatment while the US has failed, but that different policy choices create different outcomes, and evidence can guide better decisions.

Cultural and Political Context Matters

Policy doesn't exist in a vacuum. Switzerland's heroin-assisted treatment emerged from a specific crisis and political moment. Portugal's decriminalization happened under a coalition government willing to prioritize public health over tough-on-crime politics. France's pharmacy model built on a medical system with different prescribing norms than the US.

Importing policies without considering context rarely works. The US has unique characteristics: federalism that makes national policy difficult, a healthcare system built around private insurance, deep cultural ambivalence about government intervention in personal behavior, and regional variations in drug epidemics and treatment needs.

This doesn't mean learning from other countries is pointless — quite the opposite. It means identifying principles that work (low-barrier access, harm reduction, flexible dosing, reduced criminal penalties) and adapting them to American contexts rather than copying programs wholesale.

Evidence-based policy advocacy in the US can draw on international examples while recognizing that implementation will look different here than in countries with national health services or different political systems.

Lessons Worth Considering

Several themes emerge from these international comparisons:

Low-barrier access saves lives. Whether through pharmacy-based prescribing in France, safe supply in Canada, or take-home dosing in Australia, removing unnecessary obstacles to treatment consistently improves outcomes.

Harm reduction works. Switzerland's supervised injection sites, Portugal's decriminalization, and Canada's safe supply programs all acknowledge that not everyone is ready to stop using drugs, and that keeping people alive and connected to care matters even when complete abstinence isn't immediate.

Treatment should feel normal. France's pharmacy model and Australia's progression to autonomy both recognize that addiction treatment works better when it's integrated into regular healthcare rather than segregated into specialized, stigmatized systems.

Evidence matters more than ideology. Every country discussed here faced political opposition to their approaches, but they prioritized data over fear. Decades later, the results justify those choices.

One size doesn't fit all. Different patients need different approaches. Some do well on buprenorphine through telehealth, others need daily structure, still others require more intensive support. Effective systems offer options rather than forcing everyone through identical pathways.

The Future of US Opioid Treatment Policy

American addiction treatment policy is evolving. Telehealth has expanded access in ways that would have seemed impossible a decade ago. Stigma is slowly decreasing as more people understand that opioid use disorder is a medical condition, not a moral failing. Naloxone is increasingly available without prescription in many states.

At the same time, the US faces unique challenges: a fentanyl-contaminated drug supply that makes street use extraordinarily dangerous, continued insurance barriers despite parity laws, and political polarization that makes evidence-based policy difficult.

Looking at how other countries have addressed similar challenges doesn't provide simple answers, but it does show what's possible when public health guides policy. The US doesn't need to adopt heroin-assisted treatment or decriminalize all drugs to improve outcomes — but it could expand telehealth access, reduce prescribing barriers, increase take-home dosing flexibility, and fund harm reduction programs.

The countries discussed here started where the US is now: facing crises, dealing with stigma, and debating the best path forward. They made different choices, collected data, and adjusted based on evidence. That's the real lesson — not that any single policy is perfect, but